Pinnacle Wealth Management LLC Acquires 29,704 Shares of Hims & Hers Health, Inc. $HIMS

Pinnacle Wealth Management LLC raised its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 198.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 44,650 shares of the company’s stock after acquiring an additional 29,704 shares during the quarter. Hims & Hers Health comprises approximately 1.9% of Pinnacle Wealth Management LLC’s portfolio, making the stock its 25th biggest holding. Pinnacle Wealth Management LLC’s holdings in Hims & Hers Health were worth $2,226,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Northern Trust Corp increased its holdings in shares of Hims & Hers Health by 19.5% in the first quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock worth $71,969,000 after purchasing an additional 397,310 shares during the period. Yong Rong HK Asset Management Ltd increased its holdings in shares of Hims & Hers Health by 41.2% in the first quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company’s stock worth $70,920,000 after purchasing an additional 700,100 shares during the period. Nuveen LLC bought a new position in shares of Hims & Hers Health in the first quarter worth $58,403,000. BIT Capital GmbH increased its holdings in shares of Hims & Hers Health by 7.4% in the first quarter. BIT Capital GmbH now owns 1,642,493 shares of the company’s stock worth $48,536,000 after purchasing an additional 112,949 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in shares of Hims & Hers Health by 1.2% in the first quarter. Bank of New York Mellon Corp now owns 1,260,292 shares of the company’s stock worth $37,242,000 after purchasing an additional 15,339 shares during the period. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Down 15.9%

HIMS opened at $49.77 on Friday. The stock has a market cap of $11.25 billion, a PE ratio of 62.21, a P/E/G ratio of 3.40 and a beta of 2.25. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. Hims & Hers Health, Inc. has a 52 week low of $18.33 and a 52 week high of $72.98. The business’s fifty day simple moving average is $51.01 and its 200 day simple moving average is $48.89.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. During the same period in the prior year, the company earned $0.06 EPS. The firm’s revenue was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Irene Becklund sold 8,410 shares of the company’s stock in a transaction dated Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total transaction of $424,705.00. Following the completion of the sale, the insider directly owned 1,418 shares in the company, valued at $71,609. This represents a 85.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Oluyemi Okupe sold 11,595 shares of the company’s stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $57.72, for a total transaction of $669,263.40. Following the sale, the chief financial officer owned 70,232 shares of the company’s stock, valued at approximately $4,053,791.04. The trade was a 14.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,561,799 shares of company stock valued at $80,686,085. 13.71% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on HIMS. UBS Group set a $30.00 price target on shares of Hims & Hers Health in a report on Monday, June 23rd. Zacks Research cut shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Hims & Hers Health in a report on Tuesday, October 14th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $68.00 price target on shares of Hims & Hers Health in a report on Friday, September 12th. Finally, Wall Street Zen cut Hims & Hers Health from a “buy” rating to a “hold” rating in a research note on Monday, July 28th. Two investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and an average price target of $38.92.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.